Two drugs approved by the Food and Drug Administration for blood cancer treatment may also be used to treat triple negative breast and kidney cancer, researchers say. The drugs are romidepsin and decitabine. Together they can activate a gene sFRP1 (secreted frizzled related protein one) that can stop the growth of cancer cells. "We now have the basis for a clinical trial aimed at providing effective therapy for two drug-resistant cancers and perhaps many more tumor types in the future," said Dr. John Copland, biologist from Mayo Clinic.
Additional coverage: International Business Times
Medical Daily by Amber Moore